Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/intravitreal-aflibercept-injection-vs-sham-as-prophylaxis-against-XiC9Jkjiyh
References (11)
-
Michael Heiferman, A. Fawzi (2019)
Progression of subclinical choroidal neovascularization in age-related macular degenerationPLoS ONE, 14
-
J. Dias, Qinqin Zhang, José Garcia, Fang Zheng, E. Motulsky, L. Roisman, Andrew Miller, Chieh-Li Chen, S. Kubach, L. Sisternes, M. Durbin, W. Feuer, Ruikang Wang, Giovanni Gregori, P. Rosenfeld (2017)
Natural History of Subclinical Neovascularization in Nonexudative Age-Related Macular Degeneration Using Swept-Source OCT Angiography.Ophthalmology, 125 2
-
J. Ambati, J. Atkinson, Bradley Gelfand (2013)
Immunology of age-related macular degenerationNature Reviews Immunology, 13
-
R. Parikh, R. Avery, Namrata Saroj, D. Thompson, K. Freund (2019)
Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab.JAMA ophthalmology
-
Steven Bailey, Omkar Thaware, Jie Wang, Ahmed Hagag, Xinbo Zhang, C. Flaxel, A. Lauer, T. Hwang, Phoebe Lin, David Huang, Yali Jia (2019)
Detection of Nonexudative Choroidal Neovascularization and Progression to Exudative Choroidal Neovascularization Using OCT Angiography.Ophthalmology. Retina
-
Jin Yang, Qinqin Zhang, E. Motulsky, Marie Thulliez, Yingying Shi, C. Lyu, L. Sisternes, M. Durbin, W. Feuer, Ruikang Wang, Giovanni Gregori, P. Rosenfeld (2019)
Two-Year Risk of Exudation in Eyes with Non-Exudative AMD and Subclinical Neovascularization Detected with Swept Source OCT Angiography.American journal of ophthalmology
-
T. Clemons, R. Milton, R. Klein, J. Seddon, F. Ferris (2003)
Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19.Ophthalmology, 112 4
-
M. Maguire, Ebenezer Daniel, Ankoor Shah, J. Grunwald, S. Hagstrom, R. Avery, Jiayan Huang, Revell Martin, D. Roth, A. Castellarin, S. Bakri, S. Fine, Daniel Martin (2013)
Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.Ophthalmology, 120 10
-
A. Kassoff, J. Kassoff, J. Buehler, M. Eglow, F. Kaufman, M. Mehu, S. Kieval, M. Mairs, B. Graig, A. Quattrocchi, David Jones, J. Locatelli, A. Ruby, A. Capon, B. Garretson, T. Hassan, M. Trese, George Williams, V. Regan, P. Manatrey, P. Streasick, L. Szydlowski, F. McIver, C. Bridges, C. Stanley, K. Cumming, B. Lewis, M. Zajechowski, R. Margherio, M. Cox, J. Werner, R. Falk, P. Siedlak, C. Neubert, M. Klein, J. Stout, A. O'Malley, A. Lauer, J. Robertson, David Wilson, C. Beardsley, H. Anderson, P. Wallace, G. Smith, S. Howard, R. Dreyer, C. Ma, R. Chenoweth, J. Zilis, M. Johnson, P. Rice, H. Daniel, H. Crider, S. Parker, K. Sherman, Daniel Martin, T. Aaberg, P. Sternberg, L. Curtis, B. Ju, J. Gilman, B. Myles, S. Strittman, C. Gentry, H. Yi, A. Capone, M. Lambert, T. Meredith, T. Aaberg, D. Saperstein, Jennifer Lim, B. Stribling, D. Armiger, R. Swords, D. Orth, T. Flood, J. Civantos, S. deBustros, K. Packo, P. Merrill, J. Cohen, C. Figliulo, C. Morrison, D. Bryant, D. Doherty, M. McVicker, T. Drefcinski, J. Seddon, M. Pinnolis, N. Davis, I. Burton, T. Taitsel, D. Walsh, J. Dubois-Moran, C. Callahan, C. Evans, K. Snow, D. Jones-Devonish, V. Crouse (2001)
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.Archives of ophthalmology, 119 10
-
Y. Yanagi, A. Mohla, Shu-Yen Lee, R. Mathur, C. Chan, I. Yeo, T. Wong, C. Cheung (2018)
Incidence of Fellow Eye Involvement in Patients With Unilateral Exudative Age-Related Macular DegenerationJAMA Ophthalmology, 136
-
I. Barbazetto, Namrata Saroj, H. Shapiro, P. Wong, Allen Ho, K. Freund (2010)
Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials.American journal of ophthalmology, 149 6
- Publisher
- American Medical Association
- Copyright
- Copyright 2021 American Medical Association. All Rights Reserved.
- ISSN
- 2168-6165
- eISSN
- 2168-6173
- DOI
- 10.1001/jamaophthalmol.2021.0221
- Publisher site
- See Article on Publisher Site
Abstract
Key PointsQuestionCan intravitreal aflibercept injection (IAI) be used as a prophylactic treatment against conversion to exudative age-related macular degeneration (eAMD) in high-risk eyes? FindingsIn a randomized, single-masked clinical trial of 128 patients at high risk for eAMD, there was no difference in the proportion of eyes converting to eAMD between the IAI (6 patients [9.5%]) and sham (7 patients [10.9%]) groups at month 24. Patients with eAMD for longer than 2 years in their fellow eye at baseline showed a lower conversion rate in the study eye compared with those with eAMD for no longer than 2 years in the fellow eye. MeaningAlthough these findings do not support IAI as a prophylactic against conversion to eAMD, such prophylaxis is needed.
Journal
JAMA Ophthalmology – American Medical Association
Published: May 18, 2021